Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera
- PMID: 28698883
- PMCID: PMC5494054
- DOI: 10.1155/2017/9876819
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera
Abstract
Background: Myeloproliferative neoplasms (MPN) encounter thromboses due to multiple known risk factors. Heparin-induced thrombocytopenia (HIT) is a thrombotic syndrome mediated by anti-platelet factor 4 (PF4)/heparin antibodies with undetermined significance for thrombosis in MPN. We hypothesized that anti-PF4/heparin Ab might occur in MPN and promote thrombosis.
Methods: Anti-PF4/heparin antibodies were analyzed in 127 MPN patients including 76 PV and 51 ET. Screening, validation testing, and isotype testing of anti-PF4/heparin Ab were correlated with disease characteristics.
Results: Anti-PF4/heparin antibodies were detected in 21% of PV and 12% of ET versus 0.3-3% in heparin-exposed patients. Validation testing confirmed anti-PF4/heparin immunoglobulins in 15% of PV and 10% of ET. Isotype testing detected 9.2% IgG and 5.3% IgM in PV and exclusively IgM in ET. IgG-positive PV patients encountered thromboses in 57.1% suggesting anti-PF4/heparin IgG may contribute to higher risk for thrombosis in MPN. Overall, 45% of PV patients experienced thromboses with 11.8% positive for anti-PF4/heparin IgG versus 7.1% in PV without thrombosis.
Conclusion: Anti-PF4/heparin antibodies occur endogenously and more frequently in MPN than upon heparin exposure. Thrombotic risk increases in anti-PF4/heparin IgG-positive PV reflecting potential implications and calling for larger, confirmatory cohorts. Anti-PF4/heparin IgG should be assessed upon thrombosis in PV to facilitate avoidance of heparin in anti-PF4/heparin IgG-positive PV.
Figures

Similar articles
-
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.J Clin Invest. 1994 Jan;93(1):81-8. doi: 10.1172/JCI116987. J Clin Invest. 1994. PMID: 8282825 Free PMC article.
-
Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia.Thromb Haemost. 2010 Aug;104(2):402-9. doi: 10.1160/TH10-01-0002. Epub 2010 Jun 10. Thromb Haemost. 2010. PMID: 20539902
-
Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.Eur J Haematol. 2006 May;76(5):420-6. doi: 10.1111/j.1600-0609.2005.00621.x. Epub 2006 Feb 6. Eur J Haematol. 2006. PMID: 16466367
-
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.J Clin Apher. 2007 Feb;22(1):31-6. doi: 10.1002/jca.20109. J Clin Apher. 2007. PMID: 17285619 Review.
-
[Anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia--review].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):457-60. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. PMID: 18426686 Review. Chinese.
Cited by
-
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too.Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):710-717. doi: 10.1182/hematology.2021000315. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889403 Free PMC article. Review.
-
Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS.Antibodies (Basel). 2022 Jan 21;11(1):7. doi: 10.3390/antib11010007. Antibodies (Basel). 2022. PMID: 35225866 Free PMC article. Review.
-
Low Incidence of Anti-PF4/Heparin Antibodies in Patients with Acute Myelogenous Leukemia.Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024057. doi: 10.4084/MJHID.2024.057. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38984091 Free PMC article. No abstract available.
-
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.Curr Hematol Malig Rep. 2021 Oct;16(5):455-463. doi: 10.1007/s11899-021-00647-z. Epub 2021 Sep 29. Curr Hematol Malig Rep. 2021. PMID: 34586561 Free PMC article. Review.
-
Candidate SNP Markers Significantly Altering the Affinity of TATA-Binding Protein for the Promoters of Human Hub Genes for Atherogenesis, Atherosclerosis and Atheroprotection.Int J Mol Sci. 2023 May 19;24(10):9010. doi: 10.3390/ijms24109010. Int J Mol Sci. 2023. PMID: 37240358 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous